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Hepatic fibrosis is an inevitable process in the progression of chronic HBV infection to hepatic cirrhosis, but its
detailed mechanism is still unknown. Clinic serum biomarkers of HBV hepatic cirrhosis were scanned by proteomic
methods. We used two-dimensional electrophoresis (2-DE) and Matrix-Assisted Laser Desorption/Ionization Time of
Flight Mass Spectrometry (MALDI-TOF-MS) to separate and identify the proteins which were differentially expressed
in the serum of patients with hepatic fibrosis compared to HBV carriers. We identified 27 differentially expressed
proteins, of which 19 proteins were up-regulated and 8 proteins were down-regulated in the serum of patients
with hepatic fibrosis compared to HBV carriers. The expression level of enolase-1 (α-enolase) was decreased while
the level of thrombospondin-1 (TSP-1) increased in the serum of patients with hepatic fibrosis by western blot.
Enolase-1 and TSP-1 may be useful as biomarkers for the clinic diagnosis of hepatic fibrosis, but further study is
necessary.
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Most patients with chronic HBV infection will develop
hepatic cirrhosis. During the process of cirrhosis, hepatic
fibrosis is an inevitable process in the development of
chronic HBV infection to hepatic cirrhosis [1,2]. Hepatic
fibrosis is an early event in cirrhosis in patients with
HBV infection. The gold standards for the diagnosis of
hepatic fibrosis are pathological staging and classification
[3]. However, biopsy of hepatic fibrosis in patients is lim-
ited by sampling error, poor compliance of patients, and
difficulty in drawing the materials from live tissue [4,5].
Methods which will achieve early diagnosis of hepatic fi-
brosis are still unknown.
The use of serum biomarkers for diagnosis of hepatic
fibrosis has many advantages including being noninva-
sive, quick to acquire data, and provides confirmation of
hepatic fibrosis in HBV infected patients faster [6].* Correspondence: Liujingxyh@163.com; fxp1029@yahoo.com.cn
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reproduction in any medium, provided the orHowever, there are no suitable serum biomarkers known
that can serve as a reliable diagnostic biomarker for hep-
atic fibrosis.
Proteomics is an effective method to obtain high-flux
protein data useful for identifying biomarkers [7]. In
this study, in an effort to identify a serum biomarker
of hepatic fibrosis, we used 2-DE and MALDI-TOF
-MS to compare proteins which were differentially
expressed in the serum of patients with hepatic fibrosis
compared to HBV carriers. We identified two proteins,
enolase-1 (α-enolase) and Thrombospondin-1 (TSP-1),
which were differentially expressed and were chosen
for further study. Our study suggests enolase-1 and
TSP-1 play important roles in the development of hep-
atic fibrosis.Materials and methods
Serum samples
Serum samples include 4 from patients with HBV
hepatic fibrosis and another 4 from HBV carriers. All
samples were from the First Xiangya Hospital of
Central South University during the period of 2008.1 to
2010.12. All patients with HBV hepatic fibrosis wereLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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The diagnostic criteria to classify a patient as an HBV
carrier were as follows: HBsAg (+), HBV DNA (+),
HBeAg or anti-HBeAb (+), and with normal level of
ALT and AST, and no abnormal histological biopsy. All
serum samples were drawn using a K3 EDTA
anticoagulation tube and stored at 4°C in the freezer
after centrifuging at 2500 rpm × 15 min The blood
plasma of the upper layer was taken using suction and
the samples were stored at −80°C.Reagents
Micro Bio Spin column and protein assay reagents
were from Bio-Rad (Hercules, CA). Mouse anti-human
GAPDH antibody was purchased from Sigma Co. Ltd.,
Mouse anti-human enolase 1, TSP-1 and secondary
antibody were purchased from Santa Cruz Co. Ltd.
ProteoExtract® Subcellular Proteome Extraction Kit was
purchased from MERCK Co. Ltd.Figure 1 Representative serum 2-DE maps of HBV hepatic fibrosis an
The protein spots marked with arrows are the twenty-seven differential pro
showing some of the proteins differentially expressed between HBV hepatiMethods
Serum sample preparation
All serum samples were transported on ice and
centrifuged at 3000 g for 15 min at 4°C. The superna-
tants were stored at −80°C until further analysis. Serum
samples from two patients with HBV hepatic fibrosis
and two HBV carriers were used for the proteomics
study. The serum samples from the other four patients
with HBV hepatic fibrosis and four HBV carriers were
used for the western blotting study.2-DE electrophoresis
Albumin was first removed from the serum samples
prior to electrophoresis. 60 μl serum were added into
180 μl combined buffer for 15 min. And Albumin were
separated by adsorbing into the spin column. Collecting
the supernatant fluid and used for 2-DE. The operation
of 2-DE was conducted according to the ProteoExtract®
Subcellular Proteome Extraction Kit manual. Serumd HBV carriers. A. Map of HBV hepatic fibrosis. B. Map of HBV carriers.
tein spots identified by MS. C. Close-up of the region of the gels
c fibrosis patients and HBV carriers.
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tion [7 mol/L urea, 2 mol/L thiourea, 0.2% DTT, 0.5%
(v/v) pH3-10 IPG buffer, and a trace of bromophenol
blue in a total volume of 450 μl]. Then, the samples were
applied to IPG strips (pH 3-10L, 24 cm) by 14 h rehy-
dration at 30 V, 1 h at 500 V, 1 h at 1000 V and 8.5 h at
8000 V to give a total of 68 kVh on IPGphor. Focused
IPG strips were equilibrated for 15 min in a solution
of 6 mol/L urea, 2% SDS, 30% glycerol, 50 mmol/L
Tris–HCl (pH 8.8), and 1% DTT, and then a further 15
min in the same solution except that DTT was replaced
by 2.5% iodoacetamide. IPG strips were removed after
isoelectric focusing and placed into 10 ml of equilibrium
A fluid [50 mmol/L Tris–HCl pH8.8, 6 mol/L urea,
30% glycerol, 1% SDS, 0.2% DTT, trace quantities of
bromophenol blue] and then 10 ml equilibrium B fluidTable 1 Differential expressed proteins identified by MALDI-T
carriers
Spot Accession number Protein name M
1 P02771 Alpha-fetoprotein 69
2 P08833 Insulin-like growth factor-binding protein 1 33
3 P02741 C-reactive protein 23
4 P19838 Nuclear factor NF-kappa-B p105 subunit 10
5 P2671 Fibrinogen alpha chain 66
6 Q03135 Caveolin-1 20
7 P05121 Plasminogen activator inhibitor 1 48
8 P00505 Aspartate aminotransferase 47
9 P01137 Transforming growth factor beta-1 40
10 P04271 Protein S100-B 10
11 P24298 Alanine aminotransferase 1 54
12 Q14116 Interleukin-18 21
13 P01375 Tumor necrosis factor 25
14 P08253 Matrix metallopeptidase 2 73
15 P01579 Interferon gamma 19
16 P01034 Cystatin-C 13
17 P05187 Alkaline phosphatase 57
18 P01033 Metalloproteinase inhibitor 1 23
19 P07996 Thrombospondin-1 25





22 P04180 Phosphatidylcholine-sterol acyltransferase 49
23 P06276 Cholinesterase 68
24 P02652 Apolipoprotein A-II 12
25 O46409 Apolipoprotein A-IV 43
26 Q6Q788 Apolipoprotein A-V 41
27 P19875 Enolase-1 47
* Hepatic fibrosis vs HBV carriers.[50 mmol/L Tris–HCl pH8.8, 6mol/L urea, 30% gly-
cerol, 1% SDS, 3% iodoacetamide, trace quantities of
bromophenol blue], and equilibrated for 15 min each.
SDS-PAGE was performed on an Ettan DALT II sys-
tem. The protein samples were degenerated for 3 min
in 100°C boiling water and then the samples were
added into the top hole of a 12.5% PAGE separation
gel on the Ettan DALT II system. Electrophoresis was
performed at 2.5W for 30 min and then 17W until
the samples reached the bottom margin of the PAGE
separation gel. G-250 was used to visualize the protein
spots in the 2-DE gels.
Image analysis
2-DE gels were scanned by an Images Scanner
used MagicScan software (Amersham Biosciences) andOF-MS between serum of HBV hepatic fibrosis and HBV
ass weight pI Sequencecoverage (%) Scores Ratio
* Function
500 5.31 19 203 ↑2.01 biomarker
200 4.9 23 262 ↑2.01 Cell growth
760 5.12 23 570 ↑2.02 calcium binding
5356 6.09 18 186 ↑2.02 DNA binding
818 7.65 8 298 ↑2.03 receptor binding
472 6.95 9 78 ↑2.03 enzyme activity
577 6.77 12 138 ↑2.11 blood coagulation
476 4.87 19 110 ↑2.26 catalytic activity
412 5.86 12 188 ↑2.29 Cell growth
713 4.43 8 154 ↑2.31 calcium binding
637 5.11 13 908 ↑2.89 catalytic activity
326 5.23 27 392 ↑2.97 signal transducer
644 5.43 18 152 ↑3.01 apoptotic process
882 6.57 30 150 ↑3.01 metastasis
348 5.67 16 335 ↑3.21 receptor binding
120 7.11 13 262 ↑3.57 enzyme activity
954 6.14 16 362 ↑3.66 hydrolase activity,
171 5.28 4 74 ↑4.21 metastasis
695 6.67 6 166 ↑7.56 blood coagulation
674 5.03 8 304 ↓2.17 Cell growth
620 5.23 25 946 ↓2.72
DNA binding
578 5.68 17 541 ↓2.88 catalytic activity
418 6.92 16 765 ↓3.12 catalytic activity
520 4.74 28 552 ↓3.22 receptor binding
294 5.74 26 550 ↓3.57 receptor binding
213 4.97 13 394 ↓3.59 receptor binding
481 7.01 12 252 ↓5.09 DNA binding
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Three separate gels were prepared for each cell line. The
gel spot pattern of each gel was summarized in a stand-
ard gel after spot matching. Thus, we obtained one
standard gel for each sample. The intensities of the spots
were quantified by calculation of spot volume after
normalization of the image using the total spot volume
normalization method multiplied by the total area of all
the spots. Proteins were identified as being differentially
expressed when the spot intensity showed a difference of
2-fold. Significant differences were determined by the
Student’s test with a set value of P < 0.05.
Protein identification by MS
All the differential spots were excised from the stained
2-DE gels using a punch. An aliquot of 1 ml 50% methyl
cyanide and 50 mol/L (NH4)2CO3 were used to decolorize
gels at 37°C for 30 min in a water bath. The tryptic peptideFigure 2 MALDI-TOF-MS analysis of differential protein spot 27. A. Th
spot 27, which was identified as enolase-1 according to the matched peak
of enolase-1.(0.1 μg/ml) was mixed with an R-cyano-4-hydroxycin-
namic acid matrix solution. One microliter of the mixture
was analyzed with a Voyager System DE-STR 4307
MALDI-TOF Mass Spectrometer (ABI) to obtain a pep-
tide mass fingerprint (PMF). All the data were searched in
a peptide mass fingerprint map database and Mascot Dis-
tiller was used to obtain the monoisotopic peak list from
the raw mass spectrometry files.
From the tandem mass spectrometry database query,
the peptide sequence tag (PKL) format file that was
generated from MS/MS was imported into the Mascot
search engine (http://www.matrixscience.com) with a
MS/MS tolerance of (±0.3 Da) to search against
SwissProt 2012_05 database (536,029 sequences; 190,
235, 160 residues). The parameters were selected as
follows:Enzyme: Trypsin; Variable modifications: Carba-
midomethyl (C), Oxidation (M); Mass values: Monoiso-
topic; Protein Mass: Unrestricted; Peptide Masse MALDI-TOF-MS mass spectrum of spot 27; B. Mascot search results of
s; C. The protein sequence coverage and matched peptides
Figure 3 Western blots of Enolase-1 and TSP-1 in the serum of
hepatic fibrosis patients and HBV carriers. A, Western blot
analysis showing changes in the expression level of enolase 1 and
TSP-1 in the serum of HBV carriers and hepatic fibrosis patients. B,
Histogram shows the expression level of the proteins in the serum
of HBV carriers and hepatic fibrosis patients as analyzed by
Bandleader 3.0 software. Note: bands 1, 2, 3, and 4 are from HBV
carriers and bands 5, 6, 7, and 8 are from HBV hepatic
fibrosis patients.
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Da. Those proteins with scores >61 were identified as
being different proteins (p < 0.05).
Western blotting
The final protein concentration was measured by the
Bradford method [8]. A 40 μg serum protein sample was
used for the gel electrophoresis in a 12% PAGE separ-
ation gel on an Ettan DALT II system. Then the samples
were electrotransferred onto a PVDF membrane. Blots
were blocked with 5% nonfat dry milk for 2 h at room
temperature, and then incubated with primary anti-
enolase 1, anti-TSP-1 for 2 h at room temperature,
followed by incubation with a horseradish peroxidase-
conjugated secondary antibody for 1 h at room tempe-
rature. The signal was visualized with an enhanced
chemiluminescence detection reagent and quantitated by
densitometry using an ImageQuant image analysis
system (Storm Optical Scanner, Molecular Dynamics).
The mouse anti-enolase 1 (1:4000, Sigma) and anti-TSP-
1(1:4000, Sigma) were detected simultaneously as load-
ing controls.
Results
Establishment of 2-DE maps of HBV carrier and hepatic
fibrosis
We obtained 38 differentially expressed spots with ≥2
fold difference between HBV carriers and hepatic fibrosis
patients. The spots were detected by MS and 27 differ-
entially expressed proteins were determined (Figure 1).
Figure 1C provides a closer view of the maps of some of
the differentially expressed proteins.
2.2 MS identification of differentially expressed pro-
teins. A total of 27 differentially expressed proteins were
identified by MALDI-TOF-MS (Table 1). The data were
searched in the SwissProt 2012_05 (536,029 sequences;
190,235,160 residues) database using the Mascot search
engine. Enolase-1 was identified as one of the differen-
tially expressed proteins and its mass finger print and
Mascot search results are shown in Figure 2. The identi-
fied proteins are involved in cell growth, receptor bind-
ing, metastasis, blood coagulation, calcium ion binding,
and DNA binding as well as some were enzymes and
biomarkers (Table 1).
2.3 Verification of differentially expression proteins by
western blot. The two proteins, enolase-1 and thrombos-
pondin-1(TSP-1) were detected by western blot in the
serum of hepatic fibrosis patients and HBV carriers.
Enolase-1 was at least 5.09-fold down-regulated in hep-
atic fibrosis patients compared to HBV carriers and
TSP-1 was at least 7.56-fold up-regulated in hepatic fi-
brosis patients compared to HBV carriers. Enolase-1 and
TSP-1 were detected in eight cases (four hepatic fibrosis
patients and four HBV carriers). The results showedthat, compared to HBV carriers, expression of enolase-1
was down regulated in the serum of patents with hepatic
fibrosis, while expression of TSP-1 was up regulated in
the serum of patients with hepatic fibrosis (Figure 3).
The results of western blot confirmed the results from
the proteomics study.
Discussion
Hepatic fibrosis is an inevitable process in the trans-
formation of chronic HBV infection to hepatic cirrhosis,
but its detailed mechanism is still unknown. Fontana
et al. retrospectively analyzed the clinical progression of
serum hepatic fibrosis markers obtained from currently
laboratory methods and discovered that these clinical
test methods can only reliably recognize advanced fibro-
sis, and cannot accurately identify the degree of fibrosis
present during the early and middle portions of its pro-
gression [9]. Therefore, identification of HBV hepatic
fibrosis biomarkers is of great significance for early diag-
nosis and prevention of fibrosis.
Serum proteomics studies serum proteins which are
readily available. However, because of proteome analysis
restrictions for sample size, highly abundant proteins
often make it difficult to separation and identify less
abundant proteins, an issue which is particularly evident
in the proteomic analyses of serum [10]. Thus, it is ne-
cessary to first remove the interfering high abundance
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we removed the albumin which improves the detection
rate of low abundance proteins with good reproducibil-
ity. A total of 27 differentially expressed genes were
found in patients with HBV hepatic fibrosis compared to
the plasma of HBV carriers, of which 19 were up-
regulated and 8 were down-regulated in the serum of
patients with HBV hepatic fibrosis.
As one of the key enzymes of glycolysis, enolase-1
(α-enolase) widely exists in many tissues and its expres-
sion varies with cellular pathological physiology, metabo-
lism, inflammation, and the state of cell development
[11,12]. Enolase-1 also plays an important role in cell
energy metabolism [13]. Enolase-1 is expressed at the
cell surface where it promotes cancer invasion, and is
subjected to a specific array of post-translational modifi-
cations, namely acetylation, methylation and phosphor-
ylation. Enolase-1 binds plasminogen at the cell surface,
enhancing local plasmin production and monocyte mi-
gration through epithelial monolayers, and promoting
matrix degradation. These data suggest an important
mechanism of inflammatory cell invasion is mediated by
increased cell-surface expression of enolase-1 [14]. Both
enolase-1 over expression and its post-translational
modifications could be of diagnostic and prognostic
value in cancer [15]. Takashima et al. analyzed the hep-
atic tissue of patients with hepatitis b virus-related hepa-
tocellular carcinoma (HCC) by proteomics analysis and
found that expression of enolase-1 was enhanced, which
is particularly apparent in poorly-differentiated HCC
[16]. Enolase-1 acts as a central element in colon cancer
susceptibility and protein biosynthesis [17]. However
there are no reports about enolase-1 and hepatic fibrosis.
Our experimental results indicated that the expression
level of enolase-1 in the serum of patients with HBV
hepatic fibrosis was significantly higher than that in
HBV carriers. Its change of concentration in the blood
may reflect the degree of hepatic fibrosis suggesting that
enolase-1 can be used as a serum marker for the predic-
tion of hepatic fibrosis.
Thrombospondin-1 (TSP-1) is a glycoprotein with a
molecular weight of 450 kDa, and is a major component
of platelets [18]. It is involved in angiogenesis and in-
flammation and the effects of TSP-1 have been studied
in numerous preclinical tumor models. Many normal
cells, including endothelial cells, fibroblasts, adipocytes,
smooth muscle cells, monocytes, and macrophages were
all founded to secrete TSP-1 [19,20]. TSP-1 binds to the
protein components of the extracellular matrix such as
fibronectin. TSP-1 is also expressed in glomerulopathies
and is considered an early marker of inflammation and
fibrosis [21].
TSP-1 can bind to various receptors and functions
in regulating cell proliferation, proteases and theactivity of transforming growth factor beta-1 (TGF-
β1) [22,23]. As an activator of TGF-β1, TSP-1 modu-
lates the functions of TGF-β1 in cardiovascular
diseases, atherosclerosis, and obesity. In addition,
TSP-1 is selectively expressed in the infracted border
suggesting that TSP-1 might inhibit the expansion of
inflammation by activating TGF-β1 [24]. TSP1 is also
a major endogenous activator of TGF-β1 in experi-
mental inflammatory glomerular disease. Regulation
of TSP-1 with regards to its influence on TGF-β1 ac-
tivity may be one of the causes of fibrosis, as TGF-β1
positively regulates HCV RNA replication which is
likely manifested in the liver fibrosis associated with
hepatitis C infection [25]. It has been reported that
TSP-1 is closely related to renal fibrosis in which
TSP-1 is highly expressed [26]. In studies of hepatic
fibrosis, TSP-1 is found to be highly expressed. TSP-1
might play an additional role in liver fibrogenesis by
stimulating angiogenesis and could be a potential tar-
get to prevent fibrogenesis in chronic inflammatory
diseases of the liver [27].
NF-κB is a transcription factor present in almost all
animal cell types. It is involved in many biological
processes such as inflammation, immunity, cell differ-
entiation, cell growth, tumorigenesis and apoptosis
[28]. Studies indicate that NF-κB and TSP-1 together,
modulated by the expression of the androgen recep-
tor, exert antitumor effects in prostate cancer [29]. In
the tumor microenvironment, TSP-1 has been shown
to suppress tumor growth by inhibiting angiogenesis
and activating TGF-β1. NF-κB mRNA expression and
activity were significantly enhanced by proteinuria-
loading and were synchronized with high expression
of TSP-1, and TGF-β1 mRNA in the kidney [30]. We
found that expression of TSP-1, TGF-β1, and NF-κB
in patients with HBV hepatic fibrosis were all signifi-
cantly higher than that in the serum of HBV carriers,
suggesting that TSP-1, TGF-β1, and NF-κB play im-
portant roles in the process of hepatic fibrosis. The
detailed mechanisms involved in the interplay be-
tween TSP-1, TGF-β1, NF-κB and hepatic fibrosis re-
quire further study.
In conclusion, using a proteomics method, we
obtained 27 differentially expressed proteins by com-
paring the serum of HBV carriers and hepatic fibrosis
patients. The 27 proteins identified by proteomic
methods are involved in cell growth, receptor binding,
metastasis, blood coagulation, calcium ion binding,
DNA binding, as well as being biomarkers and en-
zymes. Additional work is required to understand the
relationship between these proteins and hepatic fibro-
sis. The results indicated that TSP-1, TGF-β1, NF-κB,
and enolase-1 likely play important roles in the
process of hepatic fibrosis. Although the levels of
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and hepatic fibrosis patients can be detected, the rela-
tionship between the degree of liver fibrosis and their
expression needs further study.
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